PA-PROJECT-MANAGEMENT
1.4.2021 17:02:14 CEST | Business Wire | Press release
Project Management Institute (PMI) and the Peter Drucker Society Europe today announced the launch of a strategic partnership in which PMI President and CEO Sunil Prashara will join the Drucker Society International Advisory Board.
The Peter Drucker Society Europe is a non-profit organization that seeks to advance a critical, international dialogue between management practitioners, academics, and other stakeholders. Their mission is to give a new voice to management in all sectors of society, thus contributing to the continuous improvement of the practice of management. This partnership will complement PMI’s role as the world's leading association for project professionals and changemakers.
“Both organizations are non-profit entities with the shared objective of improving the practice of management in every area of society, from government and public sector to private and not-for-profit bodies,” said Richard Straub, founder and president of the Global Peter Drucker Forum, the annual conference organized by the Drucker Society Europe.
“We are enabling millions of project leaders and changemakers to make important contributions to the world,” Prashara said. “PMI’s mission—to enable individuals to make ideas reality—aligns perfectly with Peter Drucker’s legacy of rigorous thought leadership around management as a systematic discipline entailing research, teaching, and practice. I see the Drucker Forum as a key platform and partner for raising awareness of the fundamental importance of management in building functioning modern societies.”
In support of their mission, the Peter Drucker Society Europe has designated the Global Peter Drucker Forum as a strategic initiative. The forum is an international management conference held annually in Peter Drucker's home city of Vienna, Austria, and is often hailed as the "Davos of Management,” as it has become one of the leading management conferences in Europe. The Global Peter Drucker Forum 2021 is centered on the theme of “The Human Imperative: Navigating Uncertainty in the Digital Age.” Forum stakeholders will take part in a range of discussion on ways to resolve tensions between technocratic and humanistic approaches to crisis, to arrive at a synthesis of "change and continuity."
###
About Project Management Institute
Project Management Institute (PMI) is the world's leading professional association for a growing global community of millions of project professionals and changemakers worldwide.
As the world’s leading authority on project management, PMI empowers people to make ideas a reality. Through global advocacy, networking, collaboration, research, and education. PMI prepares organizations and individuals at every stage of their career journey to work smarter so they can drive success in a world of change.
Building on a proud legacy dating to 1969, PMI is a “for-purpose” organization working in nearly every country around the world to advance careers, strengthen organizational success, and enable changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
Visit us at https://www.pmi.org/ , www.projectmanagement.com , https://www.linkedin.com/company/pminstitute , www.facebook.com/PMInstitute , and on Twitter .
About Peter Drucker Society Europe Initiative
The Peter Drucker Society Europe is a practitioner-led, multi-stakeholder group that builds on Peter Drucker’s fundamental ideas and ideals with the aim of contributing to the evolution of management as a vital piece of a functioning modern society. Each year, the Drucker Society Europe hosts the Global Peter Drucker Forum, a crystallizing event where decision makers convene to discuss the future of management in a pragmatic and solution-oriented manner.
To fulfil its mission, the Peter Drucker Society Europe has established legally and financially independent nonprofit Drucker Society chapters in Austria, London, Barcelona and Mannheim. Please note that The Drucker 1996 Literary Works Trust is the owner of the service marks "Peter Drucker", "Peter F. Drucker" and "Drucker".
Learn more at www.druckerforum.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom